Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 5/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427550 | 0.87 | CYP19A1 (0.55) | PTGS2CYP19A1CALM1AKR1B1ALDH1A1 | |
| SCHEMBL8229999 | 0.85 | PTGS2 (0.65) | PTGS2CYP3A4 | |
| SCHEMBL10175240 | 0.83 | TACR1 (0.45) | PTGS2CYP19A1TACR1CALM1AKR1B1 | |
| SCHEMBL27458712 | 0.82 | CYP19A1 (0.43) | PTGS2CYP19A1TACR1CALM1AKR1B1 | |
| SCHEMBL11766486 | 0.82 | CALM1 (0.44) | PTGS2CYP19A1TACR1CALM1AKR1B1 | |
| SCHEMBL15502971 | 0.82 | TAAR1 (0.56) | CYP19A1TACR1 | |
| SCHEMBL16952389 | 0.82 | NQO1 (0.39) | CALM1CYP3A4FFAR4 | |
| SCHEMBL13980912 | 0.81 | PTGS2 (0.50) | PTGS2CYP19A1CALM1AKR1B1ALDH1A1 | |
| SCHEMBL16962402 | 0.79 | FFAR4 (0.44) | PTGS2ALDH1A1CYP3A4CYP1A1FFAR4 | |
| SCHEMBL597287 | 0.79 | FFAR4 (0.44) | PTGS2ALDH1A1CYP3A4FFAR4NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580409-B2 | Modulators of opioid receptors and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20140288050-A1 | MODULATORS OF OPIOID RECEPTORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| EP-2366699-B1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | PTGS2 2021/4885CYP19A1 1076/4885TACR1 2562/4885 |
| US-20140288050-A1 | MODULATORS OF OPIOID RECEPTORS AND METHODS OF USE THEREOF | OPRM1, OPRK1, OPRL1 | PTGS2 886/4885CYP19A1 2876/4885TACR1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.